Natural Products in Alzheimer’s Disease Therapy: Would Old Therapeutic Approaches Fix the Broken Promise of Modern Medicines?
Despite extensive progress in understanding the pathology of Alzheimer’s disease (AD) over the last 50 years, clinical trials based on the amyloid–beta (Aβ) hypothesis have kept failing in late stage human trials. As a result, just four old drugs of limited clinical outc...
Main Author: | Solomon Habtemariam |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-04-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/24/8/1519 |
Similar Items
-
Flotillin: A Promising Biomarker for Alzheimer’s Disease
by: Efthalia Angelopoulou, et al.
Published: (2020-03-01) -
Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's disease
by: Kumar Gajendra, et al.
Published: (2024-08-01) -
Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer’s Disease and Identifying Promising Drug Targets
by: Zdeněk Fišar
Published: (2022-11-01) -
Dendrimers and Derivatives as Multifunctional Nanotherapeutics for Alzheimer’s Disease
by: Débora A. Moreira, et al.
Published: (2023-03-01) -
Alzheimer’s Disease: Current and Future Treatments. A Review
by: Evelyn Chou
Published: (2014-05-01)